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Adult stem cells are undifferentiated cells that can be mobilized from the bone marrow or
other organs, home into injured tissues, and differentiate into different cell phenotypes to
serve in a repairing capacity. Furthermore, these cells can respond to inflammation and
oxidative stress by exhibiting immunomodulatory properties.The protective and reparative
roles of mesenchymal stem cells (MSCs), very small embryonic-like stem cells (VSELs),
and endothelial progenitor cells (EPCs) have primarily been examined and characterized in
auto-immune and cardiovascular diseases. Obstructive sleep apnea (OSA) is a very preva-
lent disease (4–5% of adult population and 2–3% of children) characterized by an abnormal
increase in upper airway collapsibility. Recurrent airway obstructions elicit arterial oxygen
desaturations, increased inspiratory efforts, and sleep fragmentation, which have been
associated with important long-term neurocognitive, metabolic, and cardiovascular conse-
quences. Since inflammation, oxidative stress and endothelial dysfunction are key factors
in the development of the morbid consequences of OSA, bone marrow-derived stem cells
could be important modulators of the morbid phenotype by affording a protective role.This
mini-review is focused on the recent data available on EPCs, VSELs, and MSCs in both
animal models and patients with OSA.
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ADULT BONE-MARROW DERIVED STEM CELLS AND
OBSTRUCTIVE SLEEP APNEA
Adult stem cells are undifferentiated cells that are present in most
adult tissues and more particularly in the bone marrow. Several
stimuli, such as inflammation and oxidative stress, can mobi-
lize these cells from the bone marrow into the circulating blood,
attract them to the injured site(s) and home them into these tis-
sues to enable tissue repair and regeneration, since adult stem
cells can differentiate into specialized cell types of an organ or
tissue (Tousoulis et al., 2008; Zuba-Surma et al., 2011). Whereas
some types of bone marrow-derived stem cells are relatively well
characterized – e.g., mesenchymal stem cells (MSCs) –, other
stem cell types, such as endothelial progenitor cells (EPCs) and
very small embryonic-like stem cells (VSELs), have been discov-
ered more recently, and their characterization is not as compre-
hensive. A salient finding from a very recent investigation on
adult stem cells was that these cells – in addition to their well-
known reparative functions resulting from differentiation into
tissue injured phenotypes – also participate in the physiological
responses to inflammation and other injurious challenges. The
increased understanding of the role of bone marrow-derived stem
cells in tissue and organ homeostasis has boosted research into
their potential applications in cell-therapy approaches to different
diseases, particularly those in which ischemia-reperfusion plays a
central role.
There is increasing evidence that obstructive sleep apnea (OSA)
is associated with several important cardiovascular consequences,
such as hypertension, myocardial infarction and angina pectoris,
arrhythmias,and stroke (Jelic and Le Jemtel,2008; Bradley and Flo-
ras, 2009; Kohler and Stradling, 2010; Lavie, 2012). Most of these
consequences are attributed to a common pathway, namely, accel-
erated atherogenesis (Drager et al., 2005; Jelic and Le Jemtel, 2008;
Chung et al., 2009; Kohler and Stradling, 2010; Quercioli et al.,
2010; Lurie, 2011). In fact, OSA can promote impaired vasodila-
tion (Farre et al., 2007; Nacher et al., 2009; Reichmuth et al., 2009;
Lavie, 2012), expression of pro-inflammatory and prothrombotic
factors (Nacher et al., 2007; von Kanel et al., 2007; Gozal et al., 2008;
Jelic and Le Jemtel, 2008; Lurie, 2011; Lavie, 2012), all of which
can contribute to the endothelial injury and vascular dysfunction
associated with this highly prevalent condition. The cumulative
evidence derived from extensive clinical and translational research
carried out in this field suggests that intermittent hypoxia (IH),
increased inspiratory efforts, and recurrent arousals from sleep are
the main determinants underlying the inflammatory response and
cardiovascular alterations observed in OSA (Nacher et al., 2009;
Kohler and Stradling, 2010; Almendros et al., 2011).
In the context of the primary mechanisms involved in the
inflammation and oxidative stress that characterize OSA, a strik-
ing similarity to the mechanisms underlying ischemia-reperfusion
injury becomes immediately apparent. Accordingly, the corollary
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hypothesis that adult stem cells could play a role in the pathophys-
iology of OSA and its associated end-organ morbidities would not
be farfetched, considering the known role that stem cells play in
ischemia-reperfusion injury. Therefore, it has also been suggested
that bone marrow-derived stem cells may participate in affording
protection in patients with OSA. Indeed, recent studies carried
out on both animal models and patients have provided exciting
initial evidence to support the notion that adult stem cells may
indeed play a homeostatic role in the inflammatory and endothe-
lial dysfunction processes of OSA (Carreras et al., 2009, 2010a,b;
Jelic et al., 2009; Kheirandish-Gozal et al., 2010).
ENDOTHELIAL PROGENITOR CELLS IN OSA
Endothelial progenitor cells (EPCs) are adult bone marrow-
derived stem cells involved in endothelial repair through re-
endothelization of injured vessels and neovascularization of
ischemic lesions. These cells, which can be isolated from several
reservoirs, such as circulating peripheral blood (Asahara et al.,
1997), bone marrow (Reyes et al., 2002), and cord blood (Muro-
hara et al., 2000), represent a pool of cells that contributes to
endothelial repair (Hill et al., 2003; Zampetaki et al., 2008). More-
over, cardiovascular risk has been correlated with reduced func-
tionality (Vasa et al., 2001; Hill et al., 2003) and less numbers of
circulating EPCs determined as CD34/KDR double-positive cells
(Vasa et al., 2001), and conversely, an increased EPCs functionality
has been reported as predictive of beneficial responses in different
situations associated with cardiovascular disease events (Hill et al.,
2003; Werner et al., 2005).
Studies performed in animal models have shown that a selected
number of cytokines (Takahashi et al., 1999; Amano et al., 2004;
Tousoulis et al., 2008), vascular endothelial growth factor (VEGF;
Gill et al., 2001; Amano et al., 2004), and oxidative stress (Thum
et al., 2006; Tousoulis et al., 2008) are all able to mobilize EPCs
from the bone marrow. In the clinical setting, there is increas-
ing evidence that chronic inflammation and oxidative stress may
induce EPCs dysfunction (Tousoulis et al., 2008). Therefore, the
putative protective role of these cells and their dysfunction in
some diseases open potential new therapeutic venues. For exam-
ple, transplantation of bone marrow-derived EPCs reduced infarct
volume and neurological deficits after acute focal brain ischemia-
reperfusion injury (Ohta et al., 2006). Moreover, clinical studies
carried out to date endorse the potential of therapy based on
transplantation of EPCs for several diseases, including myocar-
dial infarction and ischemic stroke (Bolli et al., 2011; Borlongan
et al., 2011).
Among the studies carried out on EPCs in OSA, these have been
carried out in both children and adult patients – and in most cases
co-morbidities involving a potential cardiovascular risk – such
as obesity – have been avoided. However, the cumulative results
currently available on the role of EPCs in OSA are controversial,
probably because these studies were performed on only a small
number of participants (Table 1) and/or the different markers
used to characterize these cells (Berger and Lavie, 2011).
For example, in adult patients with OSA, EPCs have either been
reported as increased, decreased or have remained unchanged;
in most studies however, a reduction in circulating EPCs has
emerged. Moreover, these studies suggest a potential role for EPCs
in vascular repair. Kizawa et al. (2009) reported a ∼threefold
increase in EPCs in OSA, which was reverted after treatment
with continuous positive airway pressure (CPAP). Martin et al.
(2008) found similar values of EPCs in OSA patients and con-
trols. Yun et al. (2010) did not find any differences in EPCs in
OSA patients when compared to healthy subjects, but reported
an increase in endothelial microparticles (marker of endothelial
damage) that correlated with the apnea-hypopnea index. In con-
trast with these findings, data from five recent studies reported a
decrease in EPCs in OSA patients. Jelic et al. (2008, 2009) showed
that the number of circulating EPCs in OSA patients (newly diag-
nosed with AHI≥ 5 and BMI< 30) was reduced when compared
to age-matched controls and that after 4 weeks of CPAP treat-
ment (adherence ≥ 4 h/day), the number of circulating EPCs
either normalized (Jelic et al., 2009) or even increased (Jelic et al.,
2008) compared to controls. Furthermore, a role of EPCs in
endothelial repair capacity in OSA was suggested by the negative
correlation between circulating EPCs and endothelial apoptotic
microparticles (Jelic et al., 2009). Similarly, Murri et al. (2011)
reported a reduction in circulating endothelial-specific progeni-
tor cell markers and a negative correlation with the severity of
OSA and of oxidative stress. The values of circulating endothelial-
specific progenitor cell markers also returned to control values
after 1 month of CPAP treatment. In another study, de la Peña
et al. (2008) studied OSA patients free of any other known cardio-
vascular risk factors, and reported a reduced number of circulating
EPCs, as well as an increase in plasma VEGF levels compared to
age- and sex-matched controls.
The role on EPCs in children with OSA remains virtually unex-
plored. In a pioneering study, Kheirandish-Gozal et al. (2010)
reported that not all pediatric OSA patients exhibited endothelial
dysfunction, and that the number of EPCs was inversely related to
the magnitude of endothelial dysfunction in each patient. More
specifically, those children with OSA who presented endothe-
lial dysfunction also presented lower EPCs values. In contrast,
patients with no endothelial dysfunction had increased levels of
EPCs and of the EPCs-recruiting and homing chemokine stromal-
derived factor-1α (SDF-1α) in blood when compared to controls.
These findings in children add support to the notion that EPCs
could be an essential mechanism for endothelial repair in OSA
(Kheirandish-Gozal et al., 2010).
However, the mechanisms involved in EPCs recruitment, hom-
ing, and repair in OSA are not fully known. IH could have
a potential role in EPCs mobilization through the stabiliza-
tion and up-regulation of hypoxia-inducible genes, which in
turn would increase plasma levels of VEGF (Lavie et al., 2002)
and SDF-1α. These molecules are well-known for their intrin-
sic effect on EPCs recruitment and homing to the damaged
endothelium. In this context, VEGF plasma levels are increased
in OSA patients (de la Peña et al., 2008; Gozal et al., 2008).
However, SDF-1α levels in patients could depend on the pres-
ence of endothelial dysfunction (Kheirandish-Gozal et al., 2010).
Given that EPCs can repair injured vessels by homing to the sites
of ischemia and neovascularization, it has been suggested that
EPCs could play a cardioprotective role in OSA patients, partic-
ularly in cases of acute myocardial infarction (Berger and Lavie,
2011).
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Table 1 | Bone marrow-derived stem cell studies in patients with obstructive sleep apnea (OSA) and animal models.
Reference Species Groups (n) Main results
EPCs
Kizawa et al. (2009) Human Control (38) OSA (37) EPCs were increased threefold in OSA patients with respect to controls and
decreased after 12 weeks of CPAP treatment.
Martin et al. (2008) Human Control (10) OSA (17) EPCs: no changes between OSA and control groups.
Yun et al. (2010) Human Control (22) OSA (82) EPCs: similar values in both groups. Endothelial impairment in OSA group.
de la Peña et al. (2008) Human Control (13) OSA (13) EPCs from OSA were reduced fivefold with respect to control group. OSA also
presented increased levels of VEGF but endothelial function was unaltered.
Jelic et al. (2008) Human Control (15) OSA (30) OSA group presented a fourfold reduction in circulating EPCs with respect
to controls. Levels were normalized after 4 weeks of CPAP. In addition, OSA
patients presented increased levels of oxidative stress and inflammation.
Jelic et al. (2009) Human Control (16) OSA (16) EPCs were reduced threefold with respect to controls and were inversely
related to the presence of endothelial microparticles. EPCs increased after
4 weeks of CPAP treatment.
Murri et al. (2011) Human OSA (16) Negative correlation of circulating EPCs with severity of OSA and oxida-




Human Control (20) OSA (40) Circulating EPCs were reduced in those OSA children with impaired endothelial
function (20 patients) and increased in those without it (20 patients).
VSELs
Gharib et al. (2010) Mice Control (30) (21% O2 for 48 h) Int.
hyp. (30) (21.0 and 5.7% O2 every
180 s 12 h/day for 48 h.
Intermittent hypoxia (IH) induced migration of VSELs from bone marrow to
peripheral blood. More than 1,100 genes were differentially expressed in
VSELs in response to IH.
Gharib et al. (2011) Mice Control (6) (21% FiO2 for 24 h) Chr.
Hyp. (6) (8% FiO2 for 24 h)
Hypoxia mobilized VSELs from the bone marrow to peripheral blood and
induced a distinct genome-wide transcriptional signature.
MSCs
Carreras et al. (2009) Rat Control (10) OSA (10) (60 h 15 s
each) for 5 hours
Circulating MSCs were three times higher in rats subjected to OSA than in
controls.
Carreras et al. (2010a) Rat Cont. (30) OSA (30) (60 h 15 s each)
for 5 h
Serum from apneic rats increased MSCs migration, adhesion and endothelial
wound healing compared to serum from control rats.
Carreras et al. (2010b) Rat Cont. (10) OSA (10) (60 h 15 s each)
for 5 h
IL-1α was higher in rats subjected to recurrent obstructive apneas than in con-
trols. MSCs injection reduced the IL-1α levels induced by recurrent obstructive
apneas.
EPCs, endothelial progenitor cells; MSCs, mesenchymal stem cells; VSELs, very small embryonic-like cells.
VERY SMALL EMBRYONIC-LIKE STEM CELLS IN OSA
The recently described very small embryonic-like stem cells
(VSELs) are pluripotent cells found in the bone marrow and
peripheral blood of adult humans, and also in cord blood
(Wojakowski et al., 2009). These cells, which have a small diameter
of 3–6µm, express markers of embryonic lineage, and are able
to differentiate into lineage-committed cells from the three germ
layers. It has been reported that VSELs are recruited from the bone
marrow to the peripheral blood in several human pathologies:
Crohn’s disease (Marlicz et al., 2012), stroke (Paczkowska et al.,
2009), and acute myocardial infarction (Zuba-Surma et al., 2008;
Wojakowski et al., 2009). There is also evidence that this popu-
lation of stem cells can migrate in a gradient-dependent manner
in response to cardiac developmental chemo-attractants such as
SDF-1α, leukemia inhibitory factor (LIF), and hepatocyte growth
factor (HGF) (Paczkowska et al., 2009; Gharib et al., 2010, 2011).
The transplantation of this type of adult stem cells improved left
ventricular function and myocyte hypertrophy induced in a model
of myocardial infarction (Dawn et al., 2008). It has been suggested
that the action mechanisms of VSELs could be both multilin-
eage differentiation and paracrine effects on cardiac stem cells
(Zuba-Surma et al., 2011).
The few data available on the potential role played by VSELs in
OSA have been recently obtained in mice subjected to IH (Gharib
et al., 2010) and continuous hypoxia (Gharib et al., 2011; Table 1).
Animals subjected to IH consisting of cyclical exposures to either
21% O2 or 5.7% O2 breathing air every 3 min for 12 h/day (during
the light period) for 2 days, mobilized VSELs from bone marrow
into peripheral blood, as evidenced by a sixfold increase in the
blood/bone marrow ratio of VSELs in those animals subjected
to IH, compared to normoxic controls. A principal-component
analysis of the transcriptome of VSELs showed segregation clus-
tering into two groups associated with IH and normoxia, indicat-
ing a distinct genome-wide transcriptional perturbation in these
pluripotent stem cells. In a second study by the same team, simi-
lar results were obtained in mice subjected to continuous hypoxia
(8% O2) for 24 h. Furthermore, both studies also showed increased
plasma levels of SDF-1α, HGF, and LIF, which could partly explain
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the recruitment of VSELs from bone marrow to peripheral blood
in response to continuous and IH (Gharib et al., 2010, 2011).
MESENCHYMAL STEM CELLS IN OSA
Mesenchymal stem cells (MSCs) are a heterogeneous subset of
stromal stem cells that are present in many adult tissues. MSCs can
differentiate into cells from the mesodermal lineage (adipocytes,
osteocytes, and chondrocytes), as well as into cells from other
embryonic lineages. MSCs can interact with immune cells by
modulating several effector functions, and participate in organ
homeostasis, wound healing, and slow aging processes (Williams
and Hare, 2011). MSCs can migrate to injured tissues and have
immunosuppressive effects (Semedo et al., 2009; Hoogduijn et al.,
2010). Interestingly, it has been demonstrated that chronic hypoxia
mobilizes MSCs from bone marrow into peripheral blood in rats
(Rochefort et al., 2006) and their preconditioning to hypoxia can
enhance their survival (Wei et al., 2012). Although the mechanisms
involved in their mobilization from bone marrow are not known
in detail, there is increasing evidence that chemokines (Ji et al.,
2004; Abarbanell et al., 2009; Carreras et al., 2009) and hypoxia-
inducible genes, including hypoxia-inducible factor-1α and VEGF
(Liu et al., 2011), can stimulate the migration of MSCs to injured
tissues and/or alter their function.
The potential role of MSCs in OSA has been studied recently
using an acute rat model of recurrent airway obstructions mim-
icking OSA (Carreras et al., 2009, 2010a,b; Table 1). In the initial
study, the authors reported a threefold increase in the number
of CFUs-F from circulating blood of rats subjected to recurrent
obstructive apneas (15 s apnea/min for 3 h), as compared to the
number observed in control animals under normoxia (Carreras
et al., 2009). Therefore, as in the case of other diseases and/or inju-
rious challenges (Hoogduijn et al., 2010), this study suggested that
MSCs may act as a modulator of inflammation, and could also
repair the tissue damage induced by OSA.
A second study carried out with the same animal model of
OSA showed that serum from rats subjected to recurrent obstruc-
tive apneas can activate MSCs (Carreras et al., 2010b). Specifically,
serum from apneic rats was able to increase the motility, adher-
ence, and reparative capacity of MSCs in vitro. A transwell setting
was used to assess the chemotaxis of these cells. The application
of serum from animals subjected to apneas in the lower compart-
ment produced a twofold increase in the migration of MSCs. These
findings indicate that recurrent obstructive apneas induce an early
release of chemotactic proteins into the bloodstream that can, in
turn, induce the mobilization of MSCs toward the affected tissues.
Accordingly, the MSCs displayed greater adhesion to a monolayer
of cultured endothelial cells when incubated in serum from rats
subjected to recurrent obstructive apneas. An in vitro wound heal-
ing assay revealed that endothelial wound closure (repair of the
denuded area) was greater in those endothelial cells cultured with
serum from apneic rats.
Moreover, using an acute animal model of OSA, Carreras et al.
(2010a) reported that MSCs had similar anti-inflammatory effects
to those observed for myocardial infarction (Williams and Hare,
2011), acute kidney injury (Semedo et al., 2009), colitis (Gonza-
lez et al., 2009), and rheumatoid arthritis (Gonzalez-Rey et al.,
2010). Moreover, the intravenous injection of MSCs immediately
before the application of recurrent airway obstructions markedly
reduced the early systemic inflammatory response triggered by
apneas (Carreras et al., 2010a).
CONCLUSION
The relatively limited number of currently available studies on
the potential role played by adult stem cells in OSA suggests
that these cells could play a role as a protective and reparative
homeostatic response in this sleep breathing disorder, particu-
larly with respect to its cardiovascular consequences. However,
this research approach is very new, and available data are still
scarce, particularly in the case of VSELs and MSCs. Whereas the
data on EPCs in OSA are exclusively derived from patient stud-
ies, the data on VSELs and MSCs were obtained only in animal
models. Moreover, the potential interactions between the usual
OSA co-morbidities that are associated with cardiovascular risk
(e.g., obesity, hypertension, diabetes) and their effects on the pro-
tective and reparative mechanisms of bone marrow-derived stem
cells should be also taken into account in future research into this
promising field. Specifically, a better characterization of the cir-
culating levels of different adult stem cell types before and after
CPAP treatment could help in defining different OSA pheno-
types. This information could be useful to predict the relative
risk of an individual patient to suffer cardiovascular consequences
caused by OSA. Moreover, a further step of research should pro-
vide insights into the potential use of cell therapies to prevent or
reduce the morbidity and mortality induced by this sleep breathing
disorder.
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